PharmAust Ltd
Neurizon Therapeutics Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases in Switzerland, Australia, the United States, and internationally. The company develops drug discovery intellectual property for the treatment of various cancers and neurological diseases. Its lead candidate is Monepantel (MPL), a small molecule drug which is in Phase II cli… Read more
Market Cap & Net Worth: PharmAust Ltd (ECQ)
PharmAust Ltd (F:ECQ) has a market capitalization of $49.70 Million (€48.42 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #22677 globally and #2462 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying PharmAust Ltd's stock price €0.10 by its total outstanding shares 486635008 (486.64 Million).
PharmAust Ltd Market Cap History: 2015 to 2024
PharmAust Ltd's market capitalization history from 2015 to 2024. Data shows growth from $24.98 Million to $49.70 Million (19.15% CAGR).
PharmAust Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how PharmAust Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
10.88x
PharmAust Ltd's market cap is 10.88 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $24.98 Million | $2.37 Million | -$1.93 Million | 10.53x | N/A |
| 2016 | $16.48 Million | $2.02 Million | -$3.93 Million | 8.17x | N/A |
| 2017 | $16.48 Million | $2.85 Million | -$1.34 Million | 5.78x | N/A |
| 2018 | $8.99 Million | $2.87 Million | -$2.52 Million | 3.13x | N/A |
| 2019 | $29.22 Million | $3.67 Million | -$1.55 Million | 7.96x | N/A |
| 2020 | $33.97 Million | $3.20 Million | -$1.36 Million | 10.63x | N/A |
| 2021 | $26.47 Million | $2.14 Million | -$1.34 Million | 12.37x | N/A |
| 2022 | $16.98 Million | $3.38 Million | -$1.71 Million | 5.02x | N/A |
| 2023 | $30.72 Million | $2.82 Million | -$6.21 Million | 10.88x | N/A |
Competitor Companies of ECQ by Market Capitalization
Companies near PharmAust Ltd in the global market cap rankings as of March 19, 2026.
Key companies related to PharmAust Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
PharmAust Ltd Historical Marketcap From 2015 to 2024
Between 2015 and today, PharmAust Ltd's market cap moved from $24.98 Million to $ 49.70 Million, with a yearly change of 19.15%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2024 | €49.70 Million | +61.79% |
| 2023 | €30.72 Million | +80.88% |
| 2022 | €16.98 Million | -35.85% |
| 2021 | €26.47 Million | -22.06% |
| 2020 | €33.97 Million | +16.24% |
| 2019 | €29.22 Million | +225.00% |
| 2018 | €8.99 Million | -45.45% |
| 2017 | €16.48 Million | 0.00% |
| 2016 | €16.48 Million | -34.00% |
| 2015 | €24.98 Million | -- |
End of Day Market Cap According to Different Sources
On Dec 12th, 2025 the market cap of PharmAust Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $49.70 Million USD |
| MoneyControl | $49.70 Million USD |
| MarketWatch | $49.70 Million USD |
| marketcap.company | $49.70 Million USD |
| Reuters | $49.70 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.